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Abstract: Cells have developed numerous adaptation mechanisms to external cues by controlling
signaling-pathway activity, both qualitatively and quantitatively. The Wnt/β-catenin pathway
is a highly conserved signaling pathway involved in many biological processes, including cell
proliferation, differentiation, somatic cell reprogramming, development, and cancer. The activity of
the Wnt/β-catenin pathway and the temporal dynamics of its effector β-catenin are tightly controlled
by complex regulations. The latter encompass feedback loops within the pathway (e.g., a negative
feedback loop involving Axin2, a β-catenin transcriptional target) and crosstalk interactions with
other signaling pathways. Here, we provide a review shedding light on the coupling between
Wnt/β-catenin activation levels and fluctuations across processes and cellular systems; in particular,
we focus on development, in vitro pluripotency maintenance, and cancer. Possible mechanisms
originating Wnt/β-catenin dynamic behaviors and consequently driving different cellular responses
are also reviewed, and new avenues for future research are suggested.
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1. Introduction
Wnt proteins are key mediators of cell specification and patterning in development, adult tissue
homeostasis, and stemness [1]. Mutations of Wnt pathway components can cause a wide range of
diseases, including congenital disorders [2–13] and cancer [10,14–24]. Wnts, conserved in all metazoan
animals, can trigger the activation of two distinct signaling pathways, known as “canonical” and
“noncanonical” [25]. The most studied Wnt pathway, and the focus of this review, is the canonical Wnt
signaling; β-catenin, the pathway key effector and transcriptional coactivator, mediates canonical Wnt
pathway functions. A detailed review about noncanonical Wnt signaling can be found in Reference [26].
β-catenin has a central role in directing diverse intracellular functions. It is involved in
cell–cell adhesion through interaction with the E-cadherin cell-adhesion complex and the microtubule
network [27–34], and can also trigger gene expression in complex with T-cell transcription
factor/lymphocyte enhancer factor (TCF/LEF) family members [35–44].
The amount of β-catenin protein not complexed with E-cadherin is buffered by the destruction
complex. The latter is a multiprotein complex; it consists of scaffolding proteins Axin, tumor suppressor
APC, the serine–threonine kinases glycogen synthase kinase 3 (GSK3β), and the casein kinase 1 (CK1),
and it is responsible for cytosolic β-catenin phosphorylation, ubiquitination, and degradation [45–55].
Upstream regulations of the destruction complex result in different accumulation of β-catenin in
the cytosol.
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Meanwhile, nuclear TCF proteins associate with transcriptional repressors such as Groucho
(Gro) and inhibit the expression of β-catenin target genes [56–58] (Figure 1A). When a Wnt
ligand (such as Wnt-3a) binds to the seven-pass transmembrane receptor Frizzled (Fz) and its
coreceptor, the low-density lipoprotein receptor-related protein 6 (LRP6), the signaling pathway
is activated. Axin is recruited to the membrane and the PDZ-containing protein Dishevelled (DVL) is
phosphorylated [59–61]. β-catenin is then released from the destruction complex; no longer exposed
to kinase-mediated phosphorylation, it accumulates and can translocate to the nucleus. Therein,
β-catenin has a dual function: it both displaces the transcriptional repressor complex from the DNA
and, binding to TCF1 [62], LEF1 [38,43,63–65] and TCF4 [57,66,67], it activates the transcription of
various target genes (Figure 1B). The latter, in turn, controls genes relevant for cell proliferation [68],
stemness [69–71] and differentiation [72] (an updated list can be found online on the Wnt homepage,
http://web.stanford.edu/group/nusselab/cgi-bin/wnt/).
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Figure 1. Overview of the Wnt/β-catenin pathway topology. (A) In the absence of WNT, cytosolic
β-catenin is sequ stered by the destructio complex and degraded following multiple rounds of
phosphorylation and ubiquitination. Low nuclear β-catenin enables the TCF/LEF-mediated re r ssion
of ta get genes. (B) Fol owing WNT l gand stimulation, the d struction complex is inhibite , and
β-catenin accumulates. Nuclear β-catenin displaces the repressive complex from the DNA and
drives target gene expression in co-operation with TCF/LEF transcription factors. TCF/LEF: T-cell
transcription factor/lymphocyte enhancer factor; APC: adenomatous polyposis coli; CK1: casein kinase
1; DVL: dishevelled; FZ: frizzled; GSK3β: glycogen synthase kinase 3; LRP6: low-density lipoprotein
receptor-related protein 6; Ub: ubiquitin; GRO: Groucho.
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The ability of the Wnt/β-catenin pathway to co-ordinate cell fate and homeostasis during
development and in adult tissue has been extensively studied both in vitro and in vivo (reviewed in
Reference [73]); furthermore, being the pathway misregulated in various diseases, including cancer
and diabetes, various humanized antibodies and small molecules to antagonize its activity have been
developed [37].
In this review, we focus on the specific dose- and dynamic-dependent Wnt/β-catenin signaling
roles across systems and organisms.
2. Wnt/β-Catenin Pathway Levels, Dynamics, and Spatial Organization in Development
In vivo embryogenesis relies on the interplay of signaling cascades to activate tissue- and
organism-specific differentiation programs.
Multicellular-organism development relies on gene-expression patterns and on anterior–posterior
(AP) polarity dictated by cellular positioning [74]. The Wnt pathway is one of the signaling pathways
involved in the establishment of the AP axis and in supporting proper tissue development [75,76].
Mice lacking functional β-catenin protein are unable to undergo normal gastrulation [77]. Interestingly,
excessive β-catenin accumulation is also associated with developmental defects, resulting in
misregulated mesodermal differentiation [78]. These results suggest that the levels of β-catenin might
need to be controlled and maintained within a certain threshold to properly support development.
In this regard, Kemler and colleagues demonstrated that β-catenin levels vary during mouse
development, and control all phases of embryogenesis [78,79]. Taking advantage of a conditional
β-catenin allele and the ubiquitously active ROSA26 promoter, and generating different Cre lines,
the authors showed a clear correlation between protein dosage and developmental progress in
postgastrulation embryos, with different types of tissue requiring specific levels of β-catenin [79].
In mice, the Wnt/β-catenin pathway is fundamental for the proliferation of early pancreatic progenitor
cells following cellular specification, and supports the undifferentiated state of pancreatic precursors;
pancreas-selective β-catenin depletion results in a reduced number of pancreatic islets [80–83].
In Xenopus, low or high β-catenin accumulation levels in the anterior/posterior endoderm have
been shown to maintain a foregut fate or to promote intestinal development, respectively [56,84].
In zebrafish, a key role for timing Wnt/β-catenin pathway activation was reported: upstream-pathway
component APC was shown to rely on retinoic acid biosynthesis, and to regulate the transition from
early gut endoderm into differentiated epithelial cells specifically postfertilization [85].
The importance of controlled β-catenin protein levels is also evident in murine and human
hair-follicle homeostasis, where protein absence or overexpression results in inappropriate
differentiation and/or tumor initiation [86,87]. Hair follicles rapidly form within the first two weeks
after birth. Epithelial cells first massively proliferate and then differentiate, culminating into a final
arrested phase known as telogen. In telogen, the epidermal bulge still retains stem cells that undergo
several regenerative cycles during the lifespan [88,89]. In 1994, van Genderen and colleagues reported
a detailed phenotypic analysis of the LEF1 transcription factor during development; using a targeted
gene-inactivation approach, they demonstrated that different organs, which normally express LEF1
during development, were affected. The most severe phenotype was observed in the mammary gland,
the teeth, whiskers, body hair, and the mesencephalic nucleus of the trigeminal nerve (TMN) [90].
Conversely, overexpression of LEF1 was shown to lead to de novo hair-follicle formation, similar to the
overexpression of a constitutively stable β-catenin that induced uncontrolled ectopic hair growth and
tumorigenesis [91]. Zonal activation of the canonical Wnt pathway was also found in the mesenchyme
and epithelium of the developing tooth: using the Wnt/β-catenin pathway reporter Axin2-lacZ, both
the epithelium and mesenchyme of the mandible, maxilla and nasal processes, but the frontonasal area
showed Axin2 signal [92,93].
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More recently, increased β-catenin expression was shown to force the differentiation of the
embryonic ectoderm into hair follicles and promote de novo hair-follicle induction in adult skin; on the
other hand, β-catenin depletion led to reduced proliferation of epithelial cells and premature catagen
(i.e. regression phase prior to telogen) [94]. These observations indicate a temporal “wave” of β-catenin,
with high/low levels in the initial/proliferative (and committed) phases, respectively [94]. To tip such
balance between proliferation and differentiation [95,96], members of the Wnt family are dynamically
expressed in developing hair follicles and skin, and the β-catenin protein itself shows dynamic changes
in both accumulation levels and subcellular localization [97–102]. β-catenin knockdown experiments
showed the canonical Wnt pathway is also important during hair-follicle regeneration; following
intradermal injection of β-catenin siRNA into hair-depilated skin, hair growth was delayed of about
40 days [103].
2.1. Somitogenesis
Vertebrae formation starts from cellular precursors in a process known as the segmentation
clock [104–107]; it is an oscillating network controlling the sequential subdivision of the vertebrate
embryo elongating the body axis. During this process, somites are progressively formed from the
anterior of the presomitic mesoderm (PSM), and elongate to form the body axis [108].
The mutual regulation of various signaling pathways and the resulting gradients and oscillations
of molecules guide cell positioning and control somitogenesis [109].
Notch was the first signaling pathway shown to control the process, as the majority of the
oscillatory genes are Notch-dependent [110–118]. Of note, Notch pathway impairment does not
prevent segmentation [119], hinting the involvement of other pathways in somitogenesis. Herrmann’s
group was the first reporting about the role of Wnt3a in the murine segmentation clock [119]. They
discovered that Axin2, a negative regulator of the Wnt/β-catenin pathway [50,120,121] distributes
over the PSM as a gradient and shows oscillatory dynamics in each cycle of somite formation. Axin2
periodic expression in the PSM could be to be due to its rapid and cyclic mRNA degradation, or to
periodic production. Considering the topology of the Wnt/β-catenin pathway, the latter hypothesis is
more plausible: being a transcriptional target of the canonical Wnt signaling, Axin2 is increased upon
pathway activation and, in turns, can reduce pathway activation via its participation to the destruction
complex, which reflects on decreased Axin2 transcription via a negative feedback loop [50,120].
Moreover, Axin2, similarly to Axin, might also be destabilized by Wnt signaling [122]. Crosstalk
interactions with Notch signaling have been reported: the feedback inhibition of Wnt/β-catenin
signaling via Axin2 can trigger Notch target gene activation [123]; thus, Wnt3a stimulation can activate
Axin2 expression while inhibiting Notch signaling [119]. Fibroblast growth factor (FGF) signaling has
also been observed in the PSM [124–126]: Sprouty2 or Dusp6 and Dusp4, all Fgf inhibitors, oscillate
in phase with Notch cyclic genes due to further crosstalk interactions between the Notch and FGF
pathways [126,127].
Recent in vivo studies from Wilson’s group reported differential levels of Wnt molecules during
cell specification. Two subpopulations, both pluripotent, were identified in postimplantation epiblast
stem cells (EpiSCs): a partially neuronal-like (Sox1+) fraction, expressing low Wnt/β-catenin levels,
and a fraction of progenitor cells, with intermediate activation of the Wnt pathway. Further increase
of Wnt/β-catenin signaling activity above a threshold irreversibly promotes mesendodermal and
neuromesodermal differentiation [128].
2.2. Colon-Crypt Development and Homeostasis
The intestine has a peculiar functional architecture designed to maximize the available surface
for absorbing nutrients and water. Epithelial cells invade the surrounding connective tissue to form
tubular glands known as “crypts” [129], which are a reservoir of stem cells (intestinal stem cells, ISCs)
supporting intestinal development and epithelium turnover [130,131]. The luminal portion of the
mucosa is characterized by villi, fingerlike structures composed of terminally differentiated cells [132].
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Intestinal-epithelium regeneration involves a series of events comparable to those taking place
during intestinal development at the embryonic stage. ISCs migrate from the bottom of the crypt up
to the villi; during this upward migratory process, cells are subjected to different stimuli blocking
cell proliferation and promoting differentiation into all cell types required for intestinal functions
(enterocytes, secretory goblet cells, Paneth cells, and endoenterocrine cells) [132,133]. In parallel,
new crypts are generated through the fission process in order to support consecutive regenerative
cycles [134].
The Wnt/β-catenin pathway has been demonstrated to control, in a dose-dependent manner,
intestinal epithelium homeostasis in both health and disease. Dickkopf-1 (Dkk-1)-mediated Wnt
pathway inhibition and Wnt pathway ablation are detrimental for crypt fission both in vitro and
in vivo [135,136], and increased activation of the pathway (i.e., high β-catenin levels) and impaired
cell-cell adhesion (i.e., high β-catenin levels and low E-cadherin) can trigger cancer formation [137,138].
In healthy conditions, the Wnt cascade tightly controls ISC overproliferation [139–141]: at the crypt
base, nuclear β-catenin levels are higher, as well as in Paneth cells (positioned at the bottom of small
intestinal crypts), while nuclear Wnt activity progressively decreases up the crypt–villus axis [142].
The resulting expression gradient and the different location of proliferative versus quiescent ISCs cause
specific cell responses to Wnt signaling throughout the crypt [143]. Burgess and colleagues, using
crypt explants and 3D confocal imaging, reported heterogeneous β-catenin and E-cadherin subcellular
localization and patterning within the crypt, and proposed asymmetrical crypt budding in mice [144];
the group observed similar phenotypes in in vitro cultured 3D colonoids [145].
In the crypt, Wnt acts in coordination with other signaling pathways [146], namely: Notch [147]
(regulating cell proliferation in the stem-cell niche [148]); Hedgehog (controlling proliferation of
the ISC compartment and cell lineage differentiation in both small intestine and colon [149–151]);
bone morphogenetic proteins (BMPs, belonging to the TGF-β cytokine family and required for
intestinal cell-precursor proliferation, maturation, and terminal differentiation [152], and for the
prevention of intestinal stem-cell overproliferation through inhibition of the Wnt gradient [146]); and
Hippo/YAP (relevant for intestinal tissue regeneration [153]). The complex interaction between these
pathways balances the progenitor number in the crypt, as well as their maturation and differentiation
while moving up the crypt–villus axis, given cell position and associated signaling concentration
gradients [146].
2.3. Central Nervous System
Wnt molecules and gradients regulate different aspects of nervous system development and
function in vertebrates.
Exogenous overexpression of a stable (i.e., unresponsive to destruction complex-mediated
degradation) form of β-catenin in hippocampal neuronal cultures causes an increased number of
dendritic branches in a dose-dependent manner [154]. To test the requirement of endogenous β-catenin
for proper dendrite development, Yu and Malenka impaired β-catenin binding to protein partners by
overexpressing the intracellular domain of N-cadherin and found substantial reduction in the numbers
of dendritic branches; this effect was shown to be independent of β-catenin transcriptional activity, as
Lef1 overexpression did not cause a similar phenotype. The study also showed that cultures stimulated
with potassium (which mimics the depolarizing effects of neuronal activity) present increased dendritic
growth, partially through β-catenin signaling.
The canonical Wnt pathway also guides synaptogenesis [155–157]: WNT-7a promotes axonal
remodeling by inhibiting the activity of the GSK3 kinase. Indeed, microtubule-associated proteins Tau,
MAP-1B, and MAP-2 (microtubules stabilizer) are direct GSK3 substrates. Chemical inhibition of GSK3
recapitulates the phenotype of WNT-7a expression; in contrast, WNT-7a depletion results in reduced
synaptic formation [158]. It was also found that, during synaptogenesis, N-cadherin/catenin complexes
are initially uniformly distributed across all synaptic sites of neurons but are rapidly redistributed
and restricted only to excitatory synaptic sites [159,160]. This process is also controlled by clusters
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of β-catenin and N-cadherin, which distribute in both pre- and postsynaptic compartments [160].
Additional studies indicated that dendritic morphogenesis depends on Wnt release from neighboring
cells, and support the hypothesis of spatial diffusion of Wnt during brain development and
activity [154,161,162].
The use of a β-catenin-activated promoter driving the expression of the β-galactosidase reporter
helped in defying neurons that respond to activated β-catenin during mouse development. This study
confirmed activation of the Wnt pathway in the mid-hindbrain and in the limb apical ectodermal ridge,
and identified additional activated regions like the notochord and brain endothelia [75].
3. Wnt/β-Catenin Pathway Levels and Dynamics in Pluripotency, Differentiation, and
Somatic-Cell Reprogramming
Embryonic stem cells (ESCs) are characterized by pluripotency (i.e., the potential to differentiate
into any somatic cell type) and self-renewal (i.e., the ability of pluripotent cells to divide and maintain
such potential). Pluripotency is a transient state in vivo; instead, ESCs can indefinitely be expanded
in vitro, maintaining either ground state/naive or primed pluripotency states if isolated from the
pre- or postimplantation epiblast, respectively [163]. Culture conditions are also crucial for ESC
pluripotency maintenance. Focusing on the Wnt pathway, Sato and colleagues [164] first demonstrated
that activation of the canonical pathway by GSK inhibition supports mouse ESC (mESC) in vitro
pluripotency maintenance, even in the absence of the leukaemia inhibitory factor (LIF) in the culture
medium. It was also demonstrated that Wnt pathway repression leads to mESC differentiation
toward epiblast [165]. Such results prompted the establishment of protocols in which the canonical
Wnt pathway is constantly activated chemically: the 2i/LIF culture medium combines LIF with two
inhibitors (2i), PD0325901 and CHIR99021, repressing MAPK/ERK and GSK3β, respectively [166].
Importantly, 2i/LIF medium is serum free, and enables ground-state pluripotency maintenance, with
overall homogeneous transcript levels of key pluripotency genes as compared to their pronounced
heterogeneity and temporal fluctuations in FCS/LIF cultures [167,168]. In addition, 2i/LIF confers
mESCs high efficiency in chimaera formation [169].
If and howβ-catenin transcriptional activity is relevant for pluripotency is debated: in basal conditions
(i.e., absence of pathway activators) it is negligible [170], and β-catenin establishes protein complexes with
pluripotency master regulators Nanog and Oct4. Such results suggest that Wnt canonical pathway
transcriptional signaling might be dispensable for mESC pluripotency [165,171–175]. Nevertheless,
ground-state (e.g., 2i/LIF-cultured) mESCs show pronounced nuclear β-catenin accumulation and
enhancement, but still heterogeneous transcriptional pathway activity [176]. It is still to be determined
if there is a functional relationship between nuclear β-catenin accumulation levels and ground-state
pluripotency. Instead, in FCS/LIF cultures, Kielman and colleagues demonstrated that β-catenin doses
affect mESC capacity to differentiate into the three germ layers using APC mutants and teratoma-formation
assays [177]. Notably, while promoting pluripotency maintenance in mESCs, Wnt/β-catenin signaling
also drives the differentiation of primed cells (i.e., EpiSCs) toward the mesendoderm [72].
The canonical Wnt pathway is also relevant for somatic cell reprogramming (i.e., forced conversion
of differentiated cells into pluripotent cells [178]). Wnt components are not directly targeted in the
original cocktail of overexpressed transcription factors used by Yamanaka and colleagues to reprogram
fibroblasts [179]. Nevertheless, is was shown that activation of the pathway can enhance the efficiency
of both fusion- and factor-induced mediated reprogramming [180–184]. Interestingly, others and
we reported a biphasic role of Wnt/β-catenin pathway in reprogramming, with its activation being
beneficial only in the late stages of reprogramming [176,180,181]; this effect seems to not be related to
β-catenin-mediated regulation of the cell cycle [68]. Furthermore, we reported detrimental effects of
high levels of active β-catenin on cell-fusion-mediated reprogramming (i.e., reprogramming of mouse
neural cells upon fusion with mESCs), which, instead, is enhanced by specific β-catenin doses [184].
Regarding human embryonic and induced pluripotent stem cells (hESCs and hiPSCs, respectively),
recent studies indicate that their pluripotent state resembles that of mouse EpiSCs [185], as they
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retain some futures of primed pluripotency [186,187]. As compared to mESCs, hESCs and hiPSCs
also respond differently to MEK–ERK pathway inhibition [188]; indeed, when they are cultured in
2i/LIF conditions, naive pluripotency is not supported [189]. Nevertheless, all culture protocols
recently proposed to maintain hESCs and hiPSCs in the naïve state of pluripotency rely on Gsk3
inhibition [73]; however, it was also reported that the canonical Wnt pathway promotes hESC
differentiation [190]. Ectopic expression of OCT4/KLF4 or KLF2/KLF4 or KLF2/NANOG in human
cells can stabilize their pluripotency when cultured in 2i/LIF [191] and 2i/LIF/aPKCi [192]. Recently,
a transgene-independent naïve-state medium was proposed: the so-called naive human stem-cell
medium (NHSM) contains 2i/LIF further supplemented with p38, Jun N-terminal kinase (JNK),
aPKC and RHO-associated protein kinase inhibitors, and a low amount of FGF2 and Activin A or
TGFβ1 [188]. However, this culture condition causes loss of DNA imprinting [193]; further studies
are needed to define alternative culture protocols that can promote and support naïve pluripotency
without erasing germline memory.
WNTs and their effectors are also crucial for potency maintenance in adult stem cells [165,194–197].
In vivo analysis of various APC mutants suggested that specific signaling levels are associated with
cell specification into hematopoietic stem cells, myeloid progenitors, and early thymocytes during
haematopoiesis [198]. Bone marrow (BM) from the Axin2LacZ Wnt reporter mouse model showed
differential sensitivity in reporter activity when stimulated with the canonical Wnt pathway. Furthermore,
when studying hematopoietic stem cell (HSC) differentiation in the presence of varying Wnt/β-catenin
activity, mild/intermediate levels were shown to enhance clonogenicity and myeloid differentiation, while
high levels strongly reduced the number of colonies; only a mild increase was able to confer increased
HSC repopulation potential [198].
4. β-Catenin and Cancer
Homeostasis tightly controls the number of cells within tissue, balancing cell growth and survival.
Genetic mutations or sporadic events can result in uncontrolled cell proliferation and/or increased cell
survival, which can ultimately lead to cancer initiation [199,200]. Often, dysplastic events involve the
stem-cell compartment of the tissue, which is more susceptible to mutagenic events. β-catenin is rarely
mutated in cancer, but mutations of its main protein partners and gaining function effects can confer
enhanced stability to β-catenin, causing its aberrant accumulation [201,202].
Colorectal cancer (CRC) is the first and most characterized cancer model involving the canonical
Wnt pathway. Because of APC mutations, β-catenin levels increase, and pro-proliferative genes
are activated following its nuclear translocation [38,202]. A similar cancerogenic phenotype is also
induced by mutations in others protein members of the canonical Wnt pathway, such as human
naked-cuticle homolog NKD1 [203] and protein phosphate 2A (PP2A) [204,205]. Mutations of
NKD1 have been frequently found in CRC: loss-of-function studies, using different mutants of the
wild-type gene, showed defective inhibition of Wnt/Dvl signaling [203]. NKD1 is involved in Dvl
proteasomal-mediated degradation; therefore, the inability to destabilize Dvl results in aberrant
β-catenin accumulation and increased cell proliferation. PP2A functions are related to the control
of many signaling cascades by opposing the activity of protein kinases (as reviewed in [206]).
PP2A binds to different components of the Wnt pathway, including APC and Axin, and affects
its activity both upstream and downstream of β-catenin [207–209]. Additionally, PP2A has binding
domains for NKD1 [210] and coordinates β-catenin/E-Cadherin binding with a direct effect on the
epithelial–mesenchymal transition happening during cancer initiation, ultimately balancing the ratio
between complexed and free β-catenin [211]. Indeed, mutants of the PP2A subunit Calpha fail
mesoderm differentiation and are lethal [211]. β-catenin accumulation has also been associated with
non-CRCs of the gastrointestinal tract, including the liver and the biliary tract [212–214], the connective
tissue [215], glial cells [216], and the hematopoietic system [217].
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A study on a cohort of human gastric adenocarcinomas revealed β-catenin nuclear accumulation
in 29% of samples, whereas 71% only showed membrane β-catenin staining; this study did not
investigate a possible correlation between β-catenin levels and/or intracellular localization and
cancer severity [212]. Similar results were also found in patients with hepatocarcinoma (HCC),
where 19% of samples showed β-catenin presence in the nucleus [213]. Desmoid-type fibromatosis
showed β-catenin nuclear accumulation in approximately 50% of a tumor, and this observation was
consistent across patients with wild-type β-catenin (where accumulation is likely caused by mutations
in Wnt partners) or mutated β-catenin [215]. Finally, β-catenin was found to be the driving force
of mixed-lineage leukaemia (MLL) stem-cell (LSC) development. So’s research group characterized
β-catenin translocation and canonical Wnt pathway activation during the pre-LSCs to LSCs transition
(i.e., the process that originates aggressive and drug-resistant leukaemia) and demonstrated that the
Wnt pathway is highly activated when tumorigenesis starts, while β-catenin knockdown impairs both
murine and human MLL cell proliferation [217].
The role of β-catenin in cancer is not only restricted to the proliferative advantage of cancer cells,
but also to their ability to colonize surrounding tissue, potentiating metastasis formation [218–220]
and immune-system evasion [221–224]. Transcriptional profiling of metastatic vs. nonmetastatic
breast-cancer cells showed overexpression of the canonical Wnt pathway (i.e., β-catenin and LEF1),
β-catenin target genes (i.e., c-Myc and cyclin D1), and Wnt ligands (i.e., Wnt3a-7a); secretion of Wnt
ligands might be responsible for the activation of the Wnt pathway in cells distant from a primary
tumor [218]. An alternative study about the metastatic power of melanoma cells showed that, when
overexpressed into mice, β-catenin acts in two phases: it initially reduces cell migration and only in
the second stage it promotes metastatic spread [219]. Reduced cell migration can be explained by an
autonomous property of cancer cells by which they need to be less motile in order to colonize the
primary tissue before spreading to others [219]. These observations can be reconsidered in view of
recent findings of β-catenin-mediated immune-system elusion of cancer cells: melanoma specifically
expressing constitutive active β-catenin does not present any T-cell infiltration [223]. Manicassamy
and colleagues recently proposed a molecular mechanism for tumor-induced immunosuppression,
in which increased β-catenin activity in tumor-resident dendritic cells (DCs) can lead to enhanced
activity of vitamin A-metabolizing enzymes. This results in faster retinoic acid (RA) metabolism,
with RA driving regulatory T-cell responses and immune tolerance [225]. Interestingly, in the same
work, β-catenin inhibition was shown to reduce tumor growth, opening new therapeutic avenues for
combined targeting of Wnt/β-catenin and RA metabolism pathways.
Although β-catenin is involved in many phases of cancer progression and higher levels worsen
prognosis [220,226], little is known on whether different amounts of Wnt protein accumulation relate
to specific phases of carcinogenesis.
5. Conclusions and Future Directions
The pleiotropic roles of the Wnt/β-catenin pathway in regulating multiple processes, including
embryogenesis, pluripotency, differentiation, and cancer, have been reviewed. It appears clear that the
functions of the pathway are highly cell- and context-dependent [227]; across different systems, dose-
and dynamic-dependent functions have also been shown (Figure 2).
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confirmed experimentally in mammalian cells predictions of a computational model (developed 
using Xenopus embryos data [237]) that the canonical Wnt transcriptional system can respond to β-
catenin fold changes instead of its absolute levels, possibly due to incoherent feed-forward loops in 
pathway topology [238]. The canonical Wnt pathway is coupled to the cell cycle (see References 
[239,240] for a review). Despite its established promitotic role, recent studies [102] have shown it can 
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Figure 2. Representative cellular processes influenced by (A) Wnt gradient and (B) time-varying
β-catenin levels. The cellular response can depend on both the levels of Wnt/β-catenin pathway activity
and on cellular/tissue context. (A) High/intermediate Wnt levels support both intestinal stem-cell (ISC)
and β-cell progenitor (βCP) expansion; low Wnt levels stimulate terminal differentiation of enterocytes
(EC) and β cells (βC), but sustain hematopoietic stem-cell (HSC) maintenance. Intermediate Wnt
levels are mostly associated with blood-cell commitment (T cells, T; myeloid progenitors, MP) and
enterocyte-progenitor (ECP) differentiation. (B) β-catenin oscillations control embryo patterning. High
or low levels of β-catenin can either promote or impair somatic cell reprogramming, respectively.
Feedback loops in pathway topology [120,228] and crosstalk interactions with other pathways
across species and systems [125,229–233] might be the cause of switch and oscillatory-like pathway
behaviors. Such nonlinear dynamics could explain β-catenin’s dual role in systems for which its
heterogeneous levels have been reported but not functionally characterized, such as mESCs cultured
in both naïve (i.e., serum-based) and ground-state (i.e., serum free) pluripotency media [176,234].
Mathematical models can be instrumental in providing quantitative insights into the
characteristics and dynamics of signaling pathways and coupled dynamic processes, allowing to test
hypotheses and generate in silico predictions [235]. While the validity of modeling results inevitably
depends on model parameters, assumptions, and structure [236], computational representations of
cells can be instrumental when combined with ad hoc experimental validations. An elegant work
confirmed experimentally in mammalian cells predictions of a computational model (developed using
Xenopus embryos data [237]) that the canonical Wnt transcriptional system can respond to β-catenin
fold changes instead of its absolute levels, possibly due to incoherent feed-forward loops in pathway
topology [238]. The canonical Wnt pathway is coupled to the cell cycle (see References [239,240]
for a review). Despite its established promitotic role, recent studies [102] have shown it can also
promote expression of cell-cycle negative regulators in mESCs. Given this, and the aforementioned
role of pathway gradients in tissue organogenesis and homeostasis, as well as in cell-cell adhesion,
multiscale computational models and agent-based cell-simulation frameworks might be needed to
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better formalize signaling-pathway dynamics, thanks to their ability to describe cell mechanics, 2D/3D
tissue geometries, single-cell gene expression and its coupling to cell proliferation [241–243].
Novel experimental techniques can also be instrumental to developing a better and quantitative
understanding of the role of spatial and temporal Wnt/β-catenin (and other signaling) pathway
dynamics in controlling tissue homeostasis. Three-dimensional in vitro cell clusters and organoids
enable studying processes like organogenesis and cancer development in a fully controllable
setting [244], especially when combined with genome-modification strategies such as viral transgene
delivery and CRISPR/Cas9 technology. Successful examples include the development of bladder
cancer-cell-derived organoid cultures to study the link between Wnt/β-catenin pathway activation
and cellular organization and proliferation [245]; analysis of precardiac spheroids to study Wnt and
BMP role in the specification of two-cardiac origin [246]; and the use of intestinal organoids to study
epithelial self-organization in the gut [244,247,248].
Live-cell imaging, combined with precise perturbations of signaling-pathway dynamics,
might contribute significantly to dissect how the latter control cell fate. In a recent work,
a microfluidics/imaging-based approach was developed to entrain oscillations of Notch and Wnt
signaling to predetermined external periodic forces in the anterior monolayer PSM [123]; this
experimental setup allowed to quantitatively address important questions about the crosstalk between
the two pathways, and the role of relative timing between individual pathway oscillations in the
control of mesoderm segmentation.
The use of feedback control, recently combined with microfluidics/imaging platforms to precisely
regulate gene expression in living cells [249], and with synthetic biology tools to recreate, in a
fully controllable and reproducible way, signaling-pathway activity [250,251], might open important
avenues to quantitatively study dose- and dynamic-dependent signaling functions across biological
systems, and develop ad hoc interventions in case of malfunction.
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